| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:51:59 UTC |
|---|
| HMDB ID | HMDB0015434 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Forasartan |
|---|
| Description | Forasartan, also known as SC 52458, belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond. Forasartan is a drug which is used for the treatment of hypertension. Forasartan is a strong basic compound (based on its pKa). Forasartan is a competitive and reversible ARB that competes with the angiotensin II binding site on AT1 and relaxes vascular smooth muscle, resulting in decreased blood pressure. Research demonstrates that forasartan is also significantly less potent than losartan. In humans, forasartan is involved in forasartan action pathway. Forasartan administration selectively inhibits L-type calcium channels in the plateau component of the smooth muscle cells, favoring relaxation of the smooth muscle. Forasartan also decreases heart rate by inhibiting the positive chronotropic effect of high frequency preganglionic stimuli. Forasartan is indicated for the treatment of hypertension and, similar to other ARBs, it protects the kidneys from kidney blood vessel damage caused by increased kidney blood pressure by blocking renin–angiotensin system activation. Smooth muscle contraction occurs due to increased calcium influx through the L-type calcium channels in smooth muscle cells during the plateau component, increasing the intracellular calcium and membrane potential which sustain depolarization and contraction. The dose administered ranges between 150 mg-200 mg daily. |
|---|
| Structure | CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1 InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30) |
|---|
| Synonyms | | Value | Source |
|---|
| Forasartanum | ChEBI | | SC 52458 | ChEBI | | SC-52458 | ChEBI | | 5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridine | HMDB | | Fora-sartan | HMDB |
|
|---|
| Chemical Formula | C23H28N8 |
|---|
| Average Molecular Weight | 416.522 |
|---|
| Monoisotopic Molecular Weight | 416.243692936 |
|---|
| IUPAC Name | 5-[(dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine |
|---|
| Traditional Name | forasartan |
|---|
| CAS Registry Number | 145216-43-9 |
|---|
| SMILES | CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1 |
|---|
| InChI Identifier | InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30) |
|---|
| InChI Key | YONOBYIBNBCDSJ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Pyridines and derivatives |
|---|
| Sub Class | Phenylpyridines |
|---|
| Direct Parent | Phenylpyridines |
|---|
| Alternative Parents | |
|---|
| Substituents | - 2-phenylpyridine
- Phenyltetrazole
- Benzenoid
- Monocyclic benzene moiety
- Heteroaromatic compound
- 1,2,4-triazole
- Tetrazole
- Azole
- Azacycle
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0067 g/L | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.29 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.2771 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.16 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 44.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2293.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 251.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 206.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 181.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 221.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 608.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 549.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 84.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1249.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 460.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1689.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 354.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 360.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 229.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 174.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 12.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Forasartan,1TMS,isomer #1 | CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C)N=N3)N=C2)C(CCCC)=N1 | 3901.5 | Semi standard non polar | 33892256 | | Forasartan,1TMS,isomer #1 | CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C)N=N3)N=C2)C(CCCC)=N1 | 3822.3 | Standard non polar | 33892256 | | Forasartan,1TMS,isomer #1 | CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C)N=N3)N=C2)C(CCCC)=N1 | 4962.5 | Standard polar | 33892256 | | Forasartan,1TBDMS,isomer #1 | CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C(C)(C)C)N=N3)N=C2)C(CCCC)=N1 | 4003.4 | Semi standard non polar | 33892256 | | Forasartan,1TBDMS,isomer #1 | CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C(C)(C)C)N=N3)N=C2)C(CCCC)=N1 | 4025.6 | Standard non polar | 33892256 | | Forasartan,1TBDMS,isomer #1 | CCCCC1=NN(CC2=CC=C(C3=CC=CC=C3C3=NN([Si](C)(C)C(C)(C)C)N=N3)N=C2)C(CCCC)=N1 | 4893.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Forasartan GC-MS (Non-derivatized) - 70eV, Positive | splash10-00dr-2119100000-e04b6124d350613840ca | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Forasartan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 10V, Positive-QTOF | splash10-014i-0011900000-82f2b8054d8a70abdd4b | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 20V, Positive-QTOF | splash10-00kr-0239300000-c761990a428a03b7d031 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 40V, Positive-QTOF | splash10-0a4r-3492000000-1caaf1e75870b4c29d8a | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 10V, Negative-QTOF | splash10-00lr-0900500000-3aed9e02ff522163c56e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 20V, Negative-QTOF | splash10-00lr-0932400000-34fac54d64efb89db092 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 40V, Negative-QTOF | splash10-001i-9610000000-e6e63055f5e11a58ec4a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 10V, Positive-QTOF | splash10-014i-0000900000-e582bd677f5dc3d1574c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 20V, Positive-QTOF | splash10-014i-0014900000-15e9aca84c5d255c5adf | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 40V, Positive-QTOF | splash10-052r-2493000000-2306fba8af7044bc7838 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 10V, Negative-QTOF | splash10-014i-0000900000-d5987697aba0ae95495c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 20V, Negative-QTOF | splash10-014i-0029800000-6bb80664ce7eeee384d3 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Forasartan 40V, Negative-QTOF | splash10-00xr-2964000000-2e9a6c661f210ddd8343 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|